Skip to main content
Premium Trial:

Request an Annual Quote

Twist Bioscience Fiscal Q3 Revenues Grow 65 Percent

NEW YORK – Twist Bioscience reported a 65 percent year-over-year increase in third quarter fiscal year 2021 revenues before the opening of the market on Friday, driven by strength in next-generation sequencing revenues.

For the quarter ended June 30, Twist reported $35.0 million in revenues, up from $21.2 million during the same period last year, beating Wall Street analysts' average revenue estimate of $32.3 million.

In a conference call to discuss the financial results, Twist said that NGS revenues were $18.7 million, up twofold from $9.1 million a year ago. NGS revenues were driven by an expanding pipeline and an increase in the number of applications, including liquid biopsy. Synthetic biology revenues were $14.3 million, up 21 percent from $11.8 million a year ago. Biopharma revenue was approximately $2 million.

By region, US revenues were $ $19.2 million; revenues in Europe, the Middle East, and Africa were $12.7 million; and Asia Pacific revenues were $3.1 million.

Twist CFO Jim Thorburn said that healthcare is now Twist's largest market segment, representing nearly 50 percent of revenues, with $17.4 million, up more than twofold from $8.5 million a year ago and driven by strength in NGS. Industrial chemicals revenues were $8.4 million, a recovering academic market provided revenues of $7.7 million, and agriculture brought in about $500,000 in revenues.

The firm shipped approximately 107,000 genes in the quarter. "Ginkgo [Bioworks] now accounts for less than 10 percent of revenues," Thorburn said, "so we are no longer breaking out that activity."

Twist's research and development expenses for the quarter totaled $19.8 million, nearly double that of $10.4 million in Q3 2020, driven by increased headcount, spending on data storage technology development, and a $1.4 million grant reimbursement. Selling, general, and administrative expenses amounted to $34.5 million, up 53 percent from $22.5 million in Q3 2020, driven by $7 million in increased compensation, $3 million in outside professional services, increased headcount, and expansion into Asia and EMEA.

The firm's net loss for the quarter was $40.0 million, or $.82 per share, compared to a net loss of $28.2 million, or $.67 per share, in the year-ago quarter. Analysts, on average, had estimated a net loss of $.75 per share.

Twist used approximately 49 million shares to calculate per-share loss in the recently completed quarter, compared to about 41.8 million shares a year ago.

The company ended the quarter with $475.3 million in cash and cash equivalents and $44.1 million in short-term investments.

Twist raised its guidance for 2021 and is now expecting revenues in the range of $129 million to $132 million. This includes synthetic biology revenue in the range of $54 million to $56 million, NGS revenue in the range of $69 million to $70 million, and biopharma revenue of approximately $6 million. It expects a net loss of approximately $150 million, reflecting "increased investments in our commercial organization," the firm said in a statement.

In morning trading on the Nasdaq, shares of Twist were down 6 percent at $115.76.

The Scan

For STEM Students to Stay

New policy changes will make it easier for international STEM students to stay in the US after graduation, the Wall Street Journal reports.

To Inform or Not, To Know or Not

The New York Times writes that some genetic biobanks may re-contact donors if they spot something troublesome, but it notes that not all donors want that information.

Rapid Test Studies

Researchers are examining why rapid tests may be less effective at detecting the Omicron variant and how to improve them, NPR says.

PLOS Papers on SARS-CoV-2 Diversity in Delaware, Metastatic Breast Cancer, Adiposity GWAS

In PLOS this week: genomic analysis of SARS-CoV-2 isolates from Delaware, gene expression and protein-protein interaction patterns in metastatic breast cancer, and more.